US equities |
SPCX $173.83 ▲+1.60% NVDA $241.89 ▲+1.25% MU $1,065.76 ▲+0.17% AMD $657.25 ▲+4.04% MRVL $291.75 ▲+7.56% SNDK $1,675.45 ▼-1.68% AVGO $377.96 ▲+4.26% TSLA $380.36 ▲+0.43%
FinancialContent

Vor Biopharma Inc. - Common Stock (NQ:VOR)

18.61 +0.03 (+0.16%)
Delayed Quote Updated: 11:18 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio To Participate in Upcoming September Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints David Zaccardelli to Board of Directors
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
First and only dual BAFF/APRIL inhibitor in primary Sjögren’s disease, one of the largest autoimmune diseases without an approved therapy 
From Vor Biopharma
Via GlobeNewswire
News headline image
What's Behind The Jump In Vor Biopharma Stock? ↗
Shares of Vor Biopharma Inc. (NASDAQ: VOR) are trading higher Friday after pricing a $14.05 private placement of 5.4 million shares. 
Via Benzinga
News headline image
Vor Bio Announces $75 Million Private Placement with TCGX
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces $150 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >